Is Cabozantinib a targeted drug?

Cabozantinib (Cabozantinib) is a targeted drug. Targeted drugs refer to interfering with specific molecules or signaling pathways in tumor cells through a specific mechanism of action, thereby inhibiting the growth, proliferation and metastasis of tumor cells while minimizing damage to normal cells.

Cabotinib is a multi-target tyrosine kinase inhibitor that acts on a variety of receptor kinases and receptor tyrosine kinases, including vascular endothelial growth factor receptors (VEGFR1, VEGFR2, VEGFR3 span>), hepatocyte growth factor receptor (HGFR or c-Met), tumor-derived growth factor receptor (RET), etc. These receptors play critical roles in tumor growth, angiogenesis, metastasis, and progression. By inhibiting the activity of these receptor kinases, cabozantinib can interfere with the transmission of multiple tumor cell signaling pathways, thereby blocking tumor growth and progression.

Due to its target specificity, cabozantinib has shown potential efficacy in the treatment of tumors and has been approved for the treatment of a variety of cancers, including renal cell carcinoma, thyroid cancer, and hepatocellular carcinoma. However, each patient's condition and treatment response may be different, so when using cabozantinib, doctors need to develop a personalized treatment plan based on the patient's specific situation and closely monitor efficacy and adverse reactions.

Cabozantinib is not currently on the market in China, and therefore is not included in medical insurance. Therefore, patients cannot purchase it domestically and need to purchase it through overseas channels. There are original and generic drugs of cabozantinib abroad. The original drugs are mainly Japanese original drugs, Turkish original drugs and European version of original drugs. Foreign generic drugs are mainly Laos generic drugs and Bangladeshi generic drugs, with prices ranging from 1,300 to 2,700 yuan, and the ingredients of original drugs and generic drugs are basically the same.